- RecruitingPHASE1, PHASE2
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors
This study looks at a new drug, Mo-Rez, combined with other cancer treatments for advanced solid tumours – cancers that have spread. We want to see how safe and effective this combination is for people whose current treatments aren't working or who can't tolerate them.
For: Tumours, GynecologicalUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
This study is looking at new ways to treat advanced liver cancer that can't be removed by surgery. It combines existing medications with a new one to see if this mix works better and is safe. The aim is to find improved first-line treatments for this type of cancer.
For: Hepatocellular CarcinomaUnited States · Belgium · Brazil - RecruitingPHASE1, PHASE2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
This study looks at new ways to treat ovarian cancer that has come back after earlier treatments. It tests a new drug called Raludotatug deruxtecan (R-DXd) by itself or with other standard treatments, to see if it's safe and helps shrink the cancer.
For: Ovarian Cancer RecurrentUnited States · Israel · Spain - AuthorisedTherapeutic use (Phase IV)
An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion
This study is looking at how a treatment called bevacizumab (also known as Avastin) affects the body's defence system in people with a type of brain tumour called glioblastoma multiforme. The aim is to understand more about the disease and how well patients respond to treatment.
For: Glioblastoma multiformeHungary - RecruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
For: Endometrial Cancer · Gastric Cancer · Metastatic Castration-resistant Prostate CancerUnited States · Canada · China - Active not recruitingPHASE3
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has spread and has a specific gene change (BRAF). It compares these new combinations with standard chemotherapy to see which works best for people who haven't had treatment for their spread cancer.
For: NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
This study looks at new treatments (BNT314 and BNT327) combined with standard chemotherapy for advanced bowel (colorectal) cancer. It aims to see if this combination is safe and helps shrink or slow cancer growth, especially for patients who haven't responded well to previous treatments.
For: Metastatic Colorectal CancerUnited States · Germany · Japan - RecruitingPHASE3
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
This study offers continued treatment to cancer patients already in certain Genentech/Roche studies. It's for those still benefiting from their current treatment and who can't get it elsewhere. The aim is to bridge care for these patients.
For: CancerBelgium · Canada · China - RecruitingPHASE2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
This study looks at new treatments (Dostarlimab alone or with Bevacizumab) for certain gynaecological cancers that have come back or not responded to previous treatment, comparing them to standard chemotherapy. It aims to see which treatment works best.
For: Ovarian Neoplasms · Endometrial Neoplasms · Uterine Cervical NeoplasmsAustralia · Hong Kong · Japan - RecruitingPHASE1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This study is for adults with advanced cancers in places like the lungs or stomach that are hard to treat or have spread. It's testing a new drug, PF-08046050, to see if it's safe and helps shrink these cancers, sometimes with other medicines.
For: Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach NeoplasmsUnited States · Canada · China - Active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study is looking at new treatments for a specific type of ovarian cancer that has come back or won't go away. We want to see if these treatments are safe and effective for patients whose cancer has certain genetic features.
For: Ovarian CancerUnited States · Australia · Canada - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
This study is testing a new drug (INCA33890) alongside standard chemotherapy and another medicine (bevacizumab) for advanced bowel cancer that has spread. It aims to see if adding INCA33890 is safe and helps people live longer and feel better.
For: CRC (Colorectal Cancer)United States · Argentina · Australia - RecruitingPHASE2, PHASE3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
This study is looking at a new treatment called pumitamig, combined with chemotherapy, for people with advanced bowel cancer that hasn't been treated before. It's being compared to a standard treatment, bevacizumab with chemotherapy, to see which is safer and more effective.
For: Untreated, Unresectable, or Metastatic Colorectal CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
This study is looking at a new treatment for certain types of ovarian, fallopian tube, or peritoneal cancer that have returned after initial treatment. It compares a new drug, mirvetuximab soravtansine, given with bevacizumab, against bevacizumab alone, to see if the new combination can keep the cancer away for longer.
For: Ovarian Cancer · Peritoneal Cancer · Fallopian Tube CancerUnited States · Argentina · Australia - RecruitingPHASE1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This early-stage study is testing a new drug, INBRX-109, for people with advanced solid tumours, including certain types of Ewing sarcoma and bowel cancer. Researchers want to see if it's safe and how well it works, both alone and with standard treatments. This is for patients who haven't responded to previous therapies.
For: Ewing Sarcoma · Colorectal AdenocarcinomaUnited States · France · Italy - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - RecruitingPHASE2
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
This study is testing new treatments for a type of advanced bowel cancer that has spread. It compares a new drug called Volrustomig combined with standard chemotherapy and another drug (FOLFIRI and Bevacizumab) against the standard treatment alone, to see if adding Volrustomig is safe and effective.
For: Metastatic Colorectal CancerUnited States · Australia · Canada - Active not recruitingPHASE1, PHASE2
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
This study looks at new drug combinations for advanced cancers. We want to see if they're safe, how well they work, and what effects they have on the body. It involves different stages to find the best doses and see benefits.
For: Advanced Solid TumorsUnited States · Australia · Belgium - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This study is testing a new medicine, GDC-6036, for people with advanced cancers that have a specific genetic change called KRAS G12C. It will look at how safe the medicine is and if it helps shrink tumors, sometimes combined with other treatments.
For: Non-Small Cell Lung Cancer · Colorectal Cancer · Advanced Solid TumorsUnited States · Australia · Belgium - Active not recruitingPHASE3
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
This study looks at new treatments for ovarian cancer that has come back and is resistant to platinum-based chemotherapy. It combines existing drugs like paclitaxel and bevacizumab with a new drug called pembrolizumab, hoping to stop the cancer from growing for longer.
For: Ovarian Cancer · Carcinoma, Ovarian Epithelial · Fallopian Tube NeoplasmsUnited States · Australia · Belgium - Active not recruitingNA
Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases
This study looks at combining chemotherapy with different ways to remove or destroy tumours in people with advanced bowel cancer that has spread to many organs. The aim is to see if this combined approach helps people live longer and keeps cancer from growing for longer compared to chemotherapy alone.
For: Multi-organ Metastatic Colorectal CancerNetherlands · United Kingdom - RecruitingPHASE3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
This study looks at a new drug, Trastuzumab Deruxtecan, combined with an existing treatment, Bevacizumab, for a type of advanced ovarian cancer. It aims to see if this combination works better than Bevacizumab alone after initial chemotherapy.
For: Ovarian CancerUnited States · Australia · Austria - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
This study looks at a new drug, calderasib, for advanced bowel cancer with a specific genetic change (KRAS G12C). Researchers want to see if adding calderasib to standard treatments helps people live longer without their cancer growing.
For: Colon Adenocarcinoma · Rectal AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
This study is looking at new drug combinations for advanced cancers like ovarian, breast, lung, and stomach cancer. It checks how safe and effective they are, and how they work in the body.
For: Ovarian · Breast · SCLCUnited States · France · Israel - Active not recruitingPHASE3
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
This study is for people with cancer who are already receiving specific cancer treatments in another study. It allows them to continue their treatment if their original study ends and they can't get the medicine elsewhere. It's about safely extending access to these important cancer drugs.
For: CancerUnited States · Argentina · Australia - AuthorisedTherapeutic use (Phase IV)
A multi-centre, four-arm, randomised, double-blind study assessing the dose equivalence of bevacizumab in first-line therapy for ovarian cancer
This study is testing different doses of a drug called bevacizumab, alongside other treatments, for women with ovarian, fallopian tube, or peritoneal cancer. We want to see how well these treatments shrink tumours and if they help people live longer without their cancer getting worse.
For: Patients with ovarian cancer · fallopian tube cancer · peritoneal carcinomaPoland - RecruitingPHASE1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
This study is testing a new medicine, INCA33890, for people with advanced or spreading solid cancers. Doctors want to see how safe the medicine is, what side effects it causes, and find the best dose to give.
For: Solid Tumors · Advanced Solid Tumors · Metastatic Solid TumorsUnited States · Denmark · France - RecruitingPHASE1
Study of INCB123667 in Subjects With Advanced Solid Tumors
This study is testing a new drug, INCB123667, for people with advanced solid tumours. It will look at how safe the drug is, how it's used with other treatments, and if it could help shrink tumours. It's an early-stage study.
For: Solid TumorsUnited States · France · Italy - RecruitingPHASE2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.
For: Hepatocellular Carcinoma · Biliary Tract CancerUnited States · China · Hong Kong - RecruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This study is testing a new drug, VVD-133214, for advanced solid tumours, including a type of bowel cancer. It looks at safety, how the body handles the drug, and if it can help shrink tumours. It's an early-stage study, sometimes testing the new drug with other standard treatments.
For: Advanced Solid Tumors · Colorectal CancerUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized Phase 2 Study of ompenaclid versus placebo in combination with FOLFIRI plus bevacizumab in patients with previously treated RAS mutant advanced or metastatic colorectal cancer
This study is testing a new medicine, ompenaclid, for people with advanced bowel cancer that has a specific genetic change called a RAS mutation. It compares ompenaclid with a dummy pill when added to standard chemotherapy and another drug to see if it helps shrink tumours.
For: such as those associated with RAS mutations.Spain · Belgium · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after first-lIne chemotherapy and target agents: The HAITI study.
This study looks at a new way to treat bowel cancer that has spread only to the liver and can't be removed with surgery. It combines a special radiation treatment with regular cancer medicines to see if it can stop the cancer from growing for longer. It's for adults who have already had some chemotherapy.
For: Liver limited unresectable colorectal cancerItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer
This study is looking at new ways to treat advanced ovarian, fallopian tube, or primary peritoneal cancer before surgery. It's testing if adding new drugs to standard chemotherapy can shrink tumours more, using a simple blood test to check progress.
For: Primary peritoneal cancer/Fallopian tube cancerItaly · Spain · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-label, Phase 2 Basket Study of MK‑7684A, a Co formation of Vibostolimab (MK‑7684) With Pembrolizumab (MK‑3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (KEYVIBE 005)
This study, called KEYVIBE 005, is testing a new combination of medicines (MK-7684A, which includes vibostolimab and pembrolizumab) for people with advanced solid tumours. Researchers want to see how well this new treatment shrinks tumours and stops them from growing, either alone or with other cancer therapies.
For: Advanced solid tumorsSpain · Italy · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1)
This study is testing new ways to treat a type of liver cancer that hasn't spread far. It combines a standard treatment (TACE) with new medicines (durvalumab, sometimes with bevacizumab) to see if they help people live longer without their cancer growing.
For: Locoregional Hepatocellular Carcinoma (HCC)Italy · France · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
This study is testing a new medicine called tisotumab vedotin for advanced cervical cancer that has come back or spread. It looks at how safe the medicine is by itself and when given with other common cancer drugs, and how well it works to shrink tumours.
For: Recurrent or stage IVB cervical cancerCzechia · Netherlands · Belgium - Ongoing, recruitingPhase II and Phase III (Integrated)
A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory colorectal cancer patients (TROPHIT1)
This study is looking at a new treatment called sacituzumab govitecan for bowel cancer that has spread and isn't responding to other treatments. It compares this new drug to standard treatments to see which works best at stopping the cancer from growing.
For: Metastatic Colorectal cancer (mCRC)Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
PRODIGE 54 SAMCO : MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY IN PATIENTS WITH COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY (MSI)
This study compares a new drug, avelumab, with standard chemotherapy for advanced bowel cancer that has spread and has specific genetic changes (microsatellite instability). We want to see if avelumab can stop the cancer from growing for longer.
For: COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITYFrance - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer
This study is looking at new ways to treat advanced bowel cancer (colorectal cancer that has spread). It combines existing treatments with new drugs to see if they work better together. The aim is to find safer and more effective options for patients.
For: Metastatic colorectal cancerFrance · Italy · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
This study looks at new treatments for advanced ovarian cancer. It combines standard chemotherapy with newer drugs, durvalumab and bevacizumab, and then adds olaparib. We want to see if this combination helps patients live longer without their cancer growing.
For: Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian · fallopian or primary peritoneal cancerBelgium · Italy · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after Targeted therapies
This study looks at a new combination of existing medicines for a type of lung cancer (NSCLC) that has worsened after previous treatments. It aims to see how many patients respond positively to this new treatment approach.
For: Lung Cancer · NSCLCFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma
This study looks at new ways to treat children with neuroblastoma that has come back or not responded to previous treatments. It combines standard chemotherapy drugs with a new medicine called bevacizumab to see if this helps shrink the cancer or stop it from growing.
For: NeuroblastomaBelgium · Spain · Netherlands - RecruitingPHASE3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.
For: Hepatocellular CarcinomaUnited States · Australia · Brazil - RecruitingPHASE1
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
This study is testing a new drug, Ris-Rez, for people with advanced cancers. Researchers want to see if it's safe, how it works, and if it can help stop cancer growth, both alone and with other medicines.
For: NeoplasmsUnited States · Argentina · Canada - Active not recruitingPHASE3
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study looks at new drug combinations for advanced bowel cancer that has spread. It compares nivolumab alone, nivolumab with ipilimumab, and standard chemotherapy to see which works best for patients whose cancer has specific features (dMMR/MSI-H).
For: Metastatic Colorectal CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
This study is testing a new medicine, Sofetabart Mipitecan, for certain ovarian, fallopian tube, and peritoneal cancers. It aims to see if it works better than current treatments and is safe, for people whose cancer either has or hasn't responded well to previous platinum-based treatments.
For: Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal NeoplasmsUnited States · Australia · Austria - RecruitingPHASE3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
This study is for people with advanced bowel cancer where previous chemotherapy hasn't worked. It compares a new drug called amivantamab, plus standard FOLFIRI chemotherapy, against other established treatments (cetuximab or bevacizumab) with FOLFIRI, to see which works best.
For: Colorectal NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
For: Colorectal NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
This study looks for better ways to treat neuroblastoma in children and young people when it comes back. It tests new drug combinations to improve survival and quality of life for patients and to understand the disease better.
For: Relapsed NeuroblastomaAustralia · Austria · Belgium